RGBP Corporate Debt as of September 30, 2022 (latest published financials)Current News
While the Conventry Debt was paid off (no one has ever contested that), plenty of other debt remains. The latest Quarterly filing, from November 2022, lists the same list of outstanding debt as the 2nd Quarter filing.
On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. According to RGBP, there is also another Note (debt) issued on the same day, for the same amount (not a duplication) On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum . The maturity of the Note is three years from the issue date. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is two years from the issue date.
As of September30, 2022 $100,000 of the principal amount of the Note remains outstanding.
As of September 30, 2022 $50,000 of the principal amount of the Note remains outstanding.
As of September30, 2022 $50,000 of the principal amount of the Note remains outstanding.
As of September 30, 2022 $50,000 of the principal amount of the Note remains outstanding.
March 13, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is February 24, 2020.
As of September 30, 2022 $50,000 of the principal amount of the Note remains outstanding.
On March 31, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is March 31, 2020.
As of September 30, 2022 $50,000 of the principal amount of the Note remains outstanding.
On April 19, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is April 19, 2020.
As of September 30, 2022 $50,000 of the principal amount of the Note remains outstanding.
On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is May 5, 2020.
As of September 30, 2022 $200,000 of the principal amount of the Note remains outstanding.
On June 26, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $150,000 for consideration consisting of $150,000 cash. The Note pays simple interest in the amount of 10% per annum . The maturity of the Note is June 16, 2020.
As of September 30, 2022 $150,000 of the principal amount of the Note remains outstanding.
On September 25, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is September 25, 2020.
As of September 30, 2022 $50,000 of the principal amount of the Note remains outstanding.
On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020
As of September 30, 2022, $50,000 of the principal amount of the Note remains outstanding.
On October 16, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 9, 2020.
As of September 30, 2022 $100,000 of the principal amount of the Note remains outstanding.
On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020.
As of September 30, 2022 $25,000 of the principal amount of the Note remains outstanding.
On November 1, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $25,000 for consideration consisting of $25,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is November 1, 2020.
As of September 30 2022 $25,000 of the principal amount of the Note remains outstanding.
On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020.
As of September30, 2022 $100,000 of the principal amount of the Note remains outstanding.
On February 28, 2018 (“Issue date”) the Company issued a two Convertible Notes (“Notes”) in the aggregate face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Notes is February 28, 2021.
As of September 30, 2022 $100,000 of the principal amount of the Notes remains outstanding.
On July 11, 2018 the Company issued a Convertible Note (“Note”) in the face amount of $11,500 to an entity controlled by the Company’s then Chief Financial Officer for consideration consisting of $11,500 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 4, 2021.
As of September 30, 2022 $11,500 of the principal amount of the Note remains outstanding.
On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date
As of September 30, 2022, 10,000 of the principal amount of the Note remains outstanding.
On July 19, 2019 the Company issued a convertible promissory note in the face amount of $100,000 (“Note”) for consideration consisting of: $95,000 cash the payment of $5,000 of legal fees The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is July 19, 2020
As of September 30, 2022 $1,000 of the principal amount of the Note remains outstanding.
On July 19, 2022 Regen Biopharma, Inc. (the “Company”) issued 54,514,492 common shares (“Shares”) to Coventry Enterprises LLC in satisfaction of $180,552 of convertible indebtedness. The principal balance and accrued interest payable remaining on the $1,500,000 promissory note issued to Coventry Enterprises LLC are both$0 as of July 19,2022
Lately, there seems to be a lot of gross misunderstanding, with claims that the company has no debt. This is false, period. If you see some of the discussion, it only focuses on one debt that was paid. There is no question that is true, but these same discussions somehow ignore the many other debts. From the most recent financials filed by the company, this is the list of RGBP's current debt.
2022 Updates RGBP FAQ 1) Q: I've seen claims that RGBP has a product or products currently in Phase 1 or Phase 2 testing. Is this true?
A: Not a single document singed by the company, nor a single PR released by the company mentions ANY current FDA approved lab doing any Phase 1 or Phase 2 testing for RGBP. This will be updated, as soon as either of those are provided! Note, "clearance" is not testing.
